Proton-pump inhibitors for the treatment of functional dyspepsia

Hidekazu Suzuki, Sawako Okada, Toshifumi Hibi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In the Rome III classification, functional dyspepsia (FD) has been further subcategorized into two different syndromes, namely, epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS). Acid-related pathophysiology seems to be mainly responsible for EPS, and antisecretory agents such as proton-pump inhibitors (PPIs) seem to be effective mainly against EPS. However, recent information as to the relationship between initial duodenal acid sensitization in the early postprandial phase and delayed gastric emptying in the later postprandial phase would suggest the amelioration of PDS by antisecretory agents. In the present review, we summarized the recent literature on the direct and indirect effect of PPIs in FD (including not only Rome III, but also Rome II criteria). The effects of PPIs against FD are heterogeneous, depending on the protocol of the clinical studies, and the inclusion criteria of each randomized controlled trial (primary care or tertiary care population). As the placebo effects cannot be ignored in this disease, a placebo-controlled study would be necessary, at least for the evaluation of the effect of each agent on symptom relief in patients with FD. Further studies directly comparing PPIs with suitable placebos in terms of their effects in reducing the symptoms of endoscopically confirmed, Rome III-based FD are awaited.

Original languageEnglish
Pages (from-to)219-226
Number of pages8
JournalTherapeutic Advances in Gastroenterology
Volume4
Issue number4
DOIs
Publication statusPublished - 2011 Jul

Fingerprint

Proton Pump Inhibitors
Dyspepsia
Pain
Therapeutics
Placebos
Placebo Effect
Acids
Gastric Emptying
Tertiary Healthcare
Primary Health Care
Randomized Controlled Trials
Population

Keywords

  • antisecretory agents
  • functional gastrointestinal disorders
  • Helicobacter pylori
  • randomized controlled study
  • uninvestigated dyspepsia

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Proton-pump inhibitors for the treatment of functional dyspepsia. / Suzuki, Hidekazu; Okada, Sawako; Hibi, Toshifumi.

In: Therapeutic Advances in Gastroenterology, Vol. 4, No. 4, 07.2011, p. 219-226.

Research output: Contribution to journalArticle

Suzuki, Hidekazu ; Okada, Sawako ; Hibi, Toshifumi. / Proton-pump inhibitors for the treatment of functional dyspepsia. In: Therapeutic Advances in Gastroenterology. 2011 ; Vol. 4, No. 4. pp. 219-226.
@article{98fbaec0ef61407687a4ccb223c8dafb,
title = "Proton-pump inhibitors for the treatment of functional dyspepsia",
abstract = "In the Rome III classification, functional dyspepsia (FD) has been further subcategorized into two different syndromes, namely, epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS). Acid-related pathophysiology seems to be mainly responsible for EPS, and antisecretory agents such as proton-pump inhibitors (PPIs) seem to be effective mainly against EPS. However, recent information as to the relationship between initial duodenal acid sensitization in the early postprandial phase and delayed gastric emptying in the later postprandial phase would suggest the amelioration of PDS by antisecretory agents. In the present review, we summarized the recent literature on the direct and indirect effect of PPIs in FD (including not only Rome III, but also Rome II criteria). The effects of PPIs against FD are heterogeneous, depending on the protocol of the clinical studies, and the inclusion criteria of each randomized controlled trial (primary care or tertiary care population). As the placebo effects cannot be ignored in this disease, a placebo-controlled study would be necessary, at least for the evaluation of the effect of each agent on symptom relief in patients with FD. Further studies directly comparing PPIs with suitable placebos in terms of their effects in reducing the symptoms of endoscopically confirmed, Rome III-based FD are awaited.",
keywords = "antisecretory agents, functional gastrointestinal disorders, Helicobacter pylori, randomized controlled study, uninvestigated dyspepsia",
author = "Hidekazu Suzuki and Sawako Okada and Toshifumi Hibi",
year = "2011",
month = "7",
doi = "10.1177/1756283X11398735",
language = "English",
volume = "4",
pages = "219--226",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Proton-pump inhibitors for the treatment of functional dyspepsia

AU - Suzuki, Hidekazu

AU - Okada, Sawako

AU - Hibi, Toshifumi

PY - 2011/7

Y1 - 2011/7

N2 - In the Rome III classification, functional dyspepsia (FD) has been further subcategorized into two different syndromes, namely, epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS). Acid-related pathophysiology seems to be mainly responsible for EPS, and antisecretory agents such as proton-pump inhibitors (PPIs) seem to be effective mainly against EPS. However, recent information as to the relationship between initial duodenal acid sensitization in the early postprandial phase and delayed gastric emptying in the later postprandial phase would suggest the amelioration of PDS by antisecretory agents. In the present review, we summarized the recent literature on the direct and indirect effect of PPIs in FD (including not only Rome III, but also Rome II criteria). The effects of PPIs against FD are heterogeneous, depending on the protocol of the clinical studies, and the inclusion criteria of each randomized controlled trial (primary care or tertiary care population). As the placebo effects cannot be ignored in this disease, a placebo-controlled study would be necessary, at least for the evaluation of the effect of each agent on symptom relief in patients with FD. Further studies directly comparing PPIs with suitable placebos in terms of their effects in reducing the symptoms of endoscopically confirmed, Rome III-based FD are awaited.

AB - In the Rome III classification, functional dyspepsia (FD) has been further subcategorized into two different syndromes, namely, epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS). Acid-related pathophysiology seems to be mainly responsible for EPS, and antisecretory agents such as proton-pump inhibitors (PPIs) seem to be effective mainly against EPS. However, recent information as to the relationship between initial duodenal acid sensitization in the early postprandial phase and delayed gastric emptying in the later postprandial phase would suggest the amelioration of PDS by antisecretory agents. In the present review, we summarized the recent literature on the direct and indirect effect of PPIs in FD (including not only Rome III, but also Rome II criteria). The effects of PPIs against FD are heterogeneous, depending on the protocol of the clinical studies, and the inclusion criteria of each randomized controlled trial (primary care or tertiary care population). As the placebo effects cannot be ignored in this disease, a placebo-controlled study would be necessary, at least for the evaluation of the effect of each agent on symptom relief in patients with FD. Further studies directly comparing PPIs with suitable placebos in terms of their effects in reducing the symptoms of endoscopically confirmed, Rome III-based FD are awaited.

KW - antisecretory agents

KW - functional gastrointestinal disorders

KW - Helicobacter pylori

KW - randomized controlled study

KW - uninvestigated dyspepsia

UR - http://www.scopus.com/inward/record.url?scp=79959562285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959562285&partnerID=8YFLogxK

U2 - 10.1177/1756283X11398735

DO - 10.1177/1756283X11398735

M3 - Article

C2 - 21765866

AN - SCOPUS:79959562285

VL - 4

SP - 219

EP - 226

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 4

ER -